Compare MESO & NSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MESO | NSP |
|---|---|---|
| Founded | 2004 | 1986 |
| Country | Australia | United States |
| Employees | 108 | 4200 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.8B |
| IPO Year | 2005 | 1996 |
| Metric | MESO | NSP |
|---|---|---|
| Price | $14.52 | $46.71 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 3 |
| Target Price | N/A | ★ $47.67 |
| AVG Volume (30 Days) | 157.0K | ★ 323.9K |
| Earning Date | 02-26-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 6.45% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.97 |
| Revenue | N/A | ★ $6,812,000,000.00 |
| Revenue This Year | $629.74 | $3.45 |
| Revenue Next Year | $30.65 | $6.95 |
| P/E Ratio | ★ N/A | $49.37 |
| Revenue Growth | N/A | ★ 3.51 |
| 52 Week Low | $13.05 | $18.57 |
| 52 Week High | $21.50 | $55.90 |
| Indicator | MESO | NSP |
|---|---|---|
| Relative Strength Index (RSI) | 39.88 | 35.93 |
| Support Level | $14.18 | $37.61 |
| Resistance Level | $16.06 | $48.14 |
| Average True Range (ATR) | 0.42 | 1.85 |
| MACD | -0.08 | -0.43 |
| Stochastic Oscillator | 13.93 | 12.89 |
Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.
Insperity Inc is a company that provides a wide range of human resources and business solutions designed to help businesses improve their performance. Small and midsize enterprises are the company's primary target customers. Majority of the company's products are offered through the company's Workforce Optimization and Workforce Synchronization solutions, which comprise various human resource functions, such as payroll and employment administration, employee benefits and compensation, government compliance, performance management, training and development services, and human capital management. The company generates all of its revenue in the United States.